ACT001 Inhibits Tumor Progression and Modulates Immune Responses in Non‐Small Cell Lung Cancer
Journal of Clinical Laboratory Analysis · 2025
DOI: 10.1002/jcla.70066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, 2025. Verfasst von Zhijing Shi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Project of Tianjin Municipal Health Commission.
Abstract (Originalsprache)
Background
Advancements in non‐small cell lung cancer (NSCLC) therapies have improved outcomes, but challenges like low immune response, drug resistance, and side effects persist. ACT001, a novel small‐molecule inhibitor, shows promise in addressing these issues.
Methods
We evaluated ACT001's anti‐tumor and immunomodulatory effects in NSCLC. In vitro, its impact on proliferation, migration, invasion, and cell cycle arrest was assessed. In vivo, its effect on tumor growth in C57BL/6 mice was studied. Pull‐down assays and mass spectrometry identified ACT001's interaction with STAT1/STAT3 and its regulation of PD‐L1 expression.
Results
ACT001 inhibited NSCLC cell proliferation, migration, and invasion, induced cell cycle arrest, and suppressed tumor growth in vivo. It enhanced granzyme B release in CD3 + T cells, promoting NSCLC cell apoptosis. Mechanistically, ACT001 bound to STAT1/STAT3, suppressing their phosphorylation and reducing PD‐L1 expression.
Conclusion
ACT001 exhibits antitumoral and immunomodulatory potential by targeting STAT1/STAT3 and regulating PD‐L1, offering a promising therapeutic approach for NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China.
- Department of Respiratory and Critical Care Medicine, Tianjin Chest Hospital, Tianjin, China.
- Health Management Centre, Tianjin Medical University General Hospital, Tianjin, China.
- Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, China.
- Department of Geriatrics, Tianjin Geriatrics Institute, Tianjin Medical University General Hospital, Tianjin, China.
ORCID-Profile: Zhijing Shi
Förderung
- Science and Technology Project of Tianjin Municipal Health Commission
Zitieren
APA
Shi, Z., Li, Y., Hou, H., Wang, Z., Guo, H., Yu, Y., Song, Y., & Chen, Z. (2025). ACT001 Inhibits Tumor Progression and Modulates Immune Responses in Non‐Small Cell Lung Cancer. Journal of Clinical Laboratory Analysis. https://doi.org/10.1002/jcla.70066
Vancouver
Shi Z, Li Y, Hou H, Wang Z, Guo H, Yu Y, et al. ACT001 Inhibits Tumor Progression and Modulates Immune Responses in Non‐Small Cell Lung Cancer. Journal of Clinical Laboratory Analysis. 2025. doi:10.1002/jcla.70066
BibTeX
@article{Shi2025,
author = {Shi, Zhijing and Li, Yiman and Hou, Huijie and Wang, Zhitao and Guo, Hui and Yu, Yang and Song, Yan and Chen, Zhe},
title = {ACT001 Inhibits Tumor Progression and Modulates Immune Responses in Non‐Small Cell Lung Cancer},
journal = {Journal of Clinical Laboratory Analysis},
year = {2025},
doi = {10.1002/jcla.70066}
}
EUVIMED